Repligen (NASDAQ:RGEN) Now Covered by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $200.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. HC Wainwright reduced their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $186.00.

Repligen Trading Down 1.4 %

Shares of RGEN opened at $153.86 on Monday. The firm has a market capitalization of $8.62 billion, a price-to-earnings ratio of -415.83, a PEG ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a 50-day moving average of $155.37 and a 200 day moving average of $148.93.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the firm posted $0.23 earnings per share. The company’s revenue was up 9.7% on a year-over-year basis. On average, research analysts expect that Repligen will post 1.54 EPS for the current year.

Institutional Trading of Repligen

A number of institutional investors have recently bought and sold shares of the stock. Champlain Investment Partners LLC lifted its holdings in shares of Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares during the period. Raymond James Financial Inc. acquired a new stake in Repligen during the 4th quarter valued at approximately $52,492,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after acquiring an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. increased its stake in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the period. Finally, Two Sigma Advisers LP raised its holdings in shares of Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after purchasing an additional 102,100 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.